These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28989886)

  • 61. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
    Schernthaner G; Gross JL; Rosenstock J; Guarisco M; Fu M; Yee J; Kawaguchi M; Canovatchel W; Meininger G
    Diabetes Care; 2013 Sep; 36(9):2508-15. PubMed ID: 23564919
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.
    Tandon T; Dubey AK; Srivastava S; Manocha S; Arora E; Hasan N
    J Family Med Prim Care; 2019 Mar; 8(3):955-959. PubMed ID: 31041232
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
    Kim JD; Park CY; Cha BY; Ahn KJ; Kim IJ; Park KS; Lee HW; Min KW; Won JC; Chung MY; Kim JT; Kang JG; Park SW
    Clin Ther; 2018 May; 40(5):752-761.e2. PubMed ID: 29729957
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.
    Gottschalk M; Danne T; Vlajnic A; Cara JF
    Diabetes Care; 2007 Apr; 30(4):790-4. PubMed ID: 17392540
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
    Chakravarti HN; Nag A
    J Endocrinol Invest; 2021 Mar; 44(3):481-492. PubMed ID: 32594451
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
    Khaloo P; Asadi Komeleh S; Alemi H; Mansournia MA; Mohammadi A; Yadegar A; Afarideh M; Esteghamati S; Nakhjavani M; Esteghamati A
    J Endocrinol Invest; 2019 Jul; 42(7):851-857. PubMed ID: 30535871
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
    Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
    Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Inoue A; Atsumi T; Manda N; Kurihara Y; Aoki S;
    PLoS One; 2016; 11(10):e0164255. PubMed ID: 27711199
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).
    Yokoyama H; Hirao K; Yamaguchi K; Oishi M; Lee G; Yagi N; Takamura H; Kashiwagi A
    Jpn Clin Med; 2014; 5():33-41. PubMed ID: 25288908
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A; Lipetz R; Wu J; Schwartz S
    Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes.
    Shi C; Zhang R; Bai R; Liu D; Wang Y; Zhang X; Wang H; Du J
    Clinics (Sao Paulo); 2019; 74():e736. PubMed ID: 31038562
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
    Liu X; Wang L; Xing Y; Engel SS; Zeng L; Yao B; Xu W; Chen G; Zhang Y; Zhang R; Liu S; Weng J; Ji Q
    J Diabetes Investig; 2020 Nov; 11(6):1532-1541. PubMed ID: 32304283
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Amin NB; Aggarwal N; Pall D; Paragh G; Denney WS; Le V; Riggs M; Calle RA
    Diabetes Obes Metab; 2015 Aug; 17(8):751-9. PubMed ID: 25885172
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Dawra VK; Cutler DL; Zhou S; Krishna R; Shi H; Liang Y; Alvey C; Hickman A; Saur D; Terra SG; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):314-325. PubMed ID: 29786959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.